Risk factors

The company doubled its authorized common stock from 100,000,000 to 200,000,000 shares. Pandemic disruption risks were dropped from the filing.

The company elected to be regulated as a business development company starting January 1, 2026, shifting its regulatory regime.

The 2025 consumer price index change was updated to 2.7%, and the securities portfolio value decreased to $742.1 million.

New geopolitical risks highlight potential supply chain disruptions from baseline tariffs on imports from China, Canada, and Mexico. The company added operational and regulatory risks concerning its deployment of artificial intelligence across R&D and manufacturing. Intellectual property and clinical trial progression risks remain central to regulatory approvals for product candidates like Anaphylm.

The company entered into a $217,860,000 merger agreement with Bioserica, backed by a voting agreement from a supporting shareholder. Cash on hand dropped to $871,350 while working capital stands at $419,761 as of December 31, 2025. Shareholders approved extending the business combination deadline up to November 12, 2026.

Altisource faces heightened risks from cyber threats targeting Hubzu, lender shareholder control conflicts, and Luxembourg net operating loss expiration limits.

New risks emphasize climate exposure, cybersecurity, inflation, labor relations, and staffing as Atlas develops Brazilian lithium projects.

Black Rock Coffee Bar faces operational risks from rapid expansion, high reliance on leased real estate, and geographic concentration in the Western U.S. and Texas. Supply chain disruptions, coffee and dairy commodity inflation, and rising labor costs threaten profitability after consecutive net losses. Regulatory compliance spans food safety, state gift card laws, and evolving data privacy mandates.

Interest rate volatility and monetary policy shifts heavily influence net interest income and overall profitability.

2025 revenue fell 16.2% and billings fell 13.3%, intensifying growth risk.

Customer concentration is newly identified as a material risk: ten customers generated 52% of 2025 sales and one generated 26%.

The company added disclosures on supplier dependencies, EU drug legislation reforms, and stock price compliance. Financial restatement disclosures were expanded to cover additional quarters. Nasdaq minimum stockholders' equity requirements were added to listing risks.